Logo image
beta(2)GP1, Anti-beta(2)GP1 Antibodies and Platelets: Key Players in the Antiphospholipid Syndrome
Journal article   Open access   Peer reviewed

beta(2)GP1, Anti-beta(2)GP1 Antibodies and Platelets: Key Players in the Antiphospholipid Syndrome

Yik C. Ho, Kiran D. K. Ahuja, Heinrich Korner and Murray J. Adams
Antibodies (Basel), Vol.5(2), 12
2016
PMID: 31557993
pdf
Published885.14 kBDownloadView
CC BY V4.0 Open Access

Abstract

Immunology Life Sciences & Biomedicine Science & Technology
Anti-beta 2 glycoprotein 1 (anti-(2)GP1) antibodies are commonly found in patients with autoimmune diseases such as the antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE). Their presence is highly associated with increased risk of vascular thrombosis and/or recurrent pregnancy-related complications. Although they are a subtype of anti-phospholipid (APL) antibody, anti-(2)GP1 antibodies form complexes with (2)GP1 before binding to different receptors associated with anionic phospholipids on structures such as platelets and endothelial cells. (2)GP1 consists of five short consensus repeat termed sushi domains. It has three interchangeable conformations with a cryptic epitope at domain 1 within the molecule. Anti-(2)GP1 antibodies against this cryptic epitope are referred to as type A' antibodies, and have been suggested to be more strongly associated with both vascular and obstetric complications. In contrast, type B' antibodies, directed against other domains of (2)GP1, are more likely to be benign antibodies found in asymptomatic patients and healthy individuals. Although the interactions between anti-(2)GP1 antibodies, (2)GP1, and platelets have been investigated, the actual targeted metabolic pathway(s) and/or receptor(s) involved remain to be clearly elucidated. This review will discuss the current understanding of the interaction between anti-(2)GP1 antibodies and (2)GP1, with platelet receptors and associated signalling pathways.

Details

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Metrics

Logo image